|
|
Post by oldfishtowner on May 3, 2018 18:50:59 GMT -5
The thought did occur to me that the advisory board members where younger than the present board members. What also jumps out at you is that the Advisory Board is almost evenly divided among male and female members, whereas the Board of Directors is all male. Maybe we need a more balanced BOD. Maybe someone could do some research and suggest a few nominees for next year. |
|
|
|
Post by od on May 3, 2018 18:54:57 GMT -5
Why the fuss over grown-up pharmaceutical company blocking and tackling? We all know Scientific Advisory Boards are common. Members often sit on boards and committees for multiple manufacturers.
|
|
|
|
Post by peppy on May 3, 2018 18:55:45 GMT -5
The thought did occur to me that the advisory board members where younger than the present board members. What also jumps out at you is that the Advisory Board is almost evenly divided among male and female members, whereas the Board of Directors is all male. Maybe we need a more balanced BOD. Maybe someone could do some research and suggest a few nominees for next year. This one jumps out at me. The Minnesota connection. Elizabeth R. Seaquist, MD
—Editorial Board for the ADA's Standards of Care
• Standards of Care References76. Seaquist ER, Anderson J, Childs B, et al. Hypo- glycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endo- crine Society. Diabetes Care 2013;36:1384–1395 • PubMed www.ncbi.nlm.nih.gov/m/pubmed/?term=Seaquist+Elizabeth+R.+%5BAuthor%5D• Standards of Medical Care in Diabetes—2018 care.diabetesjournals.org/content/diacare/suppl/2017/12/08/41.Supplement_1.DC1/DC_41_S1_Combined.pdf Read more: mnkd.proboards.com/thread/9902/mnkds-sab-mangos-research#ixzz5EUCGA0Y2 |
|
|
|
Post by sayhey24 on May 3, 2018 19:08:25 GMT -5
Lois Jovanovic was speaker #13 at the ADCOM. I don't remember her saying she was on the board at the time. I wonder what happened to her. It seems she is the Chief Scientific Officer of the Sansum Diabetes Research Institute, Santa Barbara, CA now. She said she treats 4000 PWDs per year. It would be nice if she could write some afrezza scripts at Sansum. I think the new board is awesome. Great job by Dr. Kendall. Hopefully everyone on the board writes lots of afrezza scripts. Here is a niece review I saw awhile back by Anne L. Peters, MD www.medscape.com/viewarticle/887352 |
|
|
|
Post by kc on May 3, 2018 21:09:40 GMT -5
The thought did occur to me that the advisory board members where younger than the present board members. What also jumps out at you is that the Advisory Board is almost evenly divided among male and female members, whereas the Board of Directors is all male. Maybe we need a more balanced BOD. Maybe someone could do some research and suggest a few nominees for next year. You have a good point in your comment. Perhaps Mike should recruit Melinda Gates to join the MannKind Board of directors. It would be good bag a big name director. |
|
|
|
Post by bioexec25 on May 3, 2018 21:33:37 GMT -5
What also jumps out at you is that the Advisory Board is almost evenly divided among male and female members, whereas the Board of Directors is all male. Maybe we need a more balanced BOD. Maybe someone could do some research and suggest a few nominees for next year. You have a good point in your comment. Perhaps Mike should recruit Melinda Gates to join the MannKind Board of directors. It would be good bag a big name director. Or at least support from the Gates Foundation. Say $50mm a year entry level. Of course they may want to discuss access programs. |
|
|
|
Post by uvula on May 3, 2018 21:47:45 GMT -5
Where/why did steve Edelman go? He was a huge supporter.
|
|
|
|
Post by Omega on May 3, 2018 22:00:17 GMT -5
Lois Jovanovic was speaker #13 at the ADCOM. I don't remember her saying she was on the board at the time. I wonder what happened to her. It seems she is the Chief Scientific Officer of the Sansum Diabetes Research Institute, Santa Barbara, CA now. She said she treats 4000 PWDs per year. It would be nice if she could write some afrezza scripts at Sansum. I think the new board is awesome. Great job by Dr. Kendall. Hopefully everyone on the board writes lots of afrezza scripts. Here is a niece review I saw awhile back by Anne L. Peters, MD www.medscape.com/viewarticle/887352Well the word "Board" was never used on the 2011-2014 pages. They were just listed as "Scientific Advisors: Diabetes". So maybe the "Scientific Advisory Board" 2018 has a different function than the "Scientific Advisors" 2011-2014 |
|
|
|
Post by sayhey24 on May 4, 2018 5:31:40 GMT -5
Where/why did steve Edelman go? He was a huge supporter. He is not only a supporter but he uses afrezza. I think he is consulting with Onduo on their protocol. |
|
|
|
Post by mnholdem on May 4, 2018 6:10:30 GMT -5
|
|
|
|
Post by celo on May 4, 2018 8:55:42 GMT -5
Lois Jovanovic was speaker #13 at the ADCOM. I don't remember her saying she was on the board at the time. I wonder what happened to her. It seems she is the Chief Scientific Officer of the Sansum Diabetes Research Institute, Santa Barbara, CA now. She said she treats 4000 PWDs per year. It would be nice if she could write some afrezza scripts at Sansum. I think the new board is awesome. Great job by Dr. Kendall. Hopefully everyone on the board writes lots of afrezza scripts. Here is a niece review I saw awhile back by Anne L. Peters, MD www.medscape.com/viewarticle/887352Well the word "Board" was never used on the 2011-2014 pages. They were just listed as "Scientific Advisors: Diabetes". So maybe the "Scientific Advisory Board" 2018 has a different function than the "Scientific Advisors" 2011-2014 I would like to add, no one prescribes Afrezza in the Santa Barbara area. The closest prescribing doctor is an internist some 15 miles away. I guess Afrezza did not make an impression on her. |
|
|
|
Post by nylefty on May 4, 2018 11:03:25 GMT -5
Well the word "Board" was never used on the 2011-2014 pages. They were just listed as "Scientific Advisors: Diabetes". So maybe the "Scientific Advisory Board" 2018 has a different function than the "Scientific Advisors" 2011-2014 I would like to add, no one prescribes Afrezza in the Santa Barbara area. The closest prescribing doctor is an internist some 15 miles away. I guess Afrezza did not make an impression on her. How do you know that? The Find A Doctor list is presumably compiled from reports by Afrezza sales reps. But many doctors refuse to see reps and therefore aren't included on the list. |
|
|
|
Post by porkini on Mar 29, 2023 11:02:39 GMT -5
Bringing this thread out of hibernation because I noticed that it looks like the SAB is completely different members since, well, not really sure since when. Not sure if anyone else has been documenting Mannkind SAB members anywhere, but here is what is currently listed on mannkindcorp.com/about/mannkind
Scientific Advisory BoardThomas Blevins, MD, FACE, ECNU, FNLA Clinical Endocrinologist, Texas Diabetes and Endocrinology, Austin, Texas Bruce W. Bode, MD Atlanta Diabetes Associates Anders L. Carlson, MD Medical Director, International Diabetes Center Medical Director, Diabetes Education Programs, HealthPartners Medical Groups Endocrinologist, Regions Hospital & HealthPartners Clinics Associate Professor, University of Minnesota Medical School Davida F. Kruger, MSN, APN-BC, BC-ADM Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, and Bone Disorders Kashif Latif, MD AM Diabetes and Endocrinology Center, Bartlett, Tennessee Scott W. Lee, MD Medical Director Diabetes Treatment Center Professor of Medicine, LLU School of Medicine Philip Levin, MD Clinical Asst Professor Johns Hopkins University School of Medicine David Maahs, MD, PhD Associate Director, Stanford Diabetes Research Center The Kirkwood Distinguished Packard Fellow Professor of Pediatrics and, by courtesy, of Health Research and Policy (Epidemiology) Chief of Pediatric Endocrinology Lucile Packard Children’s Hospital Stanford University, School of Medicine Janet B. McGill, MD, MA, FACE, FACP Professor of Medicine Division of Endocrinology, Metabolism and Lipid Research Washington University School of Medicine |
|
|
|
Post by mango on Mar 29, 2023 11:19:14 GMT -5
Bringing this thread out of hibernation because I noticed that it looks like the SAB is completely different members since, well, not really sure since when. Not sure if anyone else has been documenting Mannkind SAB members anywhere, but here is what is currently listed on mannkindcorp.com/about/mannkind
Scientific Advisory BoardThomas Blevins, MD, FACE, ECNU, FNLA Clinical Endocrinologist, Texas Diabetes and Endocrinology, Austin, Texas Bruce W. Bode, MD Atlanta Diabetes Associates Anders L. Carlson, MD Medical Director, International Diabetes Center Medical Director, Diabetes Education Programs, HealthPartners Medical Groups Endocrinologist, Regions Hospital & HealthPartners Clinics Associate Professor, University of Minnesota Medical School Davida F. Kruger, MSN, APN-BC, BC-ADM Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, and Bone Disorders Kashif Latif, MD AM Diabetes and Endocrinology Center, Bartlett, Tennessee Scott W. Lee, MD Medical Director Diabetes Treatment Center Professor of Medicine, LLU School of Medicine Philip Levin, MD Clinical Asst Professor Johns Hopkins University School of Medicine David Maahs, MD, PhD Associate Director, Stanford Diabetes Research Center The Kirkwood Distinguished Packard Fellow Professor of Pediatrics and, by courtesy, of Health Research and Policy (Epidemiology) Chief of Pediatric Endocrinology Lucile Packard Children’s Hospital Stanford University, School of Medicine Janet B. McGill, MD, MA, FACE, FACP Professor of Medicine Division of Endocrinology, Metabolism and Lipid Research Washington University School of Medicine Just from first glance it looks like the Blevins guy and the nurse practitioner are new, or at least I don’t remember either of those originally. The others I believe are OGs. How much value any of these individuals bring forth in the awareness, advocacy, and script growth of Afrezza remains to be seen. |
|
